# Evaluating the Safety and Efficacy of the Maurora® DES in ICAS

Study · id `cardio:ct-nct05719883` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05719883](<https://clinicaltrials.gov/study/NCT05719883>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05719883

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

## Technical summary

Registry record NCT05719883. Randomized; single masking; primary purpose treatment. Start 2023-02-20 (actual); primary completion 2025-04-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 156 participants (enrolled count; ClinicalTrials.gov record NCT05719883, source copy `cardio:ctgov-nct05719883-2025-06-26`, retrieved 2026-10-26)
- Started: 2023-02-20 (actual) (ClinicalTrials.gov record NCT05719883, source copy `cardio:ctgov-nct05719883-2025-06-26`, retrieved 2026-10-26)
- Primary completion: 2025-04-30 (actual) (ClinicalTrials.gov record NCT05719883, source copy `cardio:ctgov-nct05719883-2025-06-26`, retrieved 2026-10-26)
- Completion: 2025-05-15 (actual) (ClinicalTrials.gov record NCT05719883, source copy `cardio:ctgov-nct05719883-2025-06-26`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05719883, source copy `cardio:ctgov-nct05719883-2025-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05719883-2025-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluating the Safety and Efficacy of the Maurora® DES in ICAS
- Acronym: Maurora ICAS
- Condition: Intracranial Arteriosclerosis
- Condition: Stroke (CVA) or TIA
- Intervention (Device): Maurora® Sirolimus Eluting Stent System
- Intervention (Device): APOLLO™ Intracranial Stent System
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: Alain Medical (Beijing) Co., Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 14a740be332f88cff6b12c4cb56a5262ed28906dfcc6b0e2021e82819c467520
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
